145 related articles for article (PubMed ID: 32725507)
1. Long Noncoding RNA Expression in Adrenal Cortical Neoplasms.
Shiyanbola O; Hardin H; Hu R; Eickhoff JC; Lloyd RV
Endocr Pathol; 2020 Dec; 31(4):385-391. PubMed ID: 32725507
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence.
Glover AR; Zhao JT; Ip JC; Lee JC; Robinson BG; Gill AJ; Soon PS; Sidhu SB
Endocr Relat Cancer; 2015 Feb; 22(1):99-109. PubMed ID: 25595289
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
Wang C; Sun Y; Wu H; Zhao D; Chen J
Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
[TBL] [Abstract][Full Text] [Related]
4. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.
Covach A; Patel S; Hardin H; Lloyd RV
Endocr Pathol; 2017 Sep; 28(3):207-212. PubMed ID: 28660408
[TBL] [Abstract][Full Text] [Related]
7. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
9. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
[TBL] [Abstract][Full Text] [Related]
10. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.
Buishand FO; Liu-Chittenden Y; Fan Y; Tirosh A; Gara SK; Patel D; Meerzaman D; Kebebew E
Surgery; 2020 Jan; 167(1):224-232. PubMed ID: 31522749
[TBL] [Abstract][Full Text] [Related]
12. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.
Giordano TJ
Endocr Pathol; 2006; 17(4):355-63. PubMed ID: 17525484
[TBL] [Abstract][Full Text] [Related]
14. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
de Cremoux P; Rosenberg D; Goussard J; Brémont-Weil C; Tissier F; Tran-Perennou C; Groussin L; Bertagna X; Bertherat J; Raffin-Sanson ML
Endocr Relat Cancer; 2008 Jun; 15(2):465-74. PubMed ID: 18508999
[TBL] [Abstract][Full Text] [Related]
15. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
[TBL] [Abstract][Full Text] [Related]
16. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
Blanes A; Diaz-Cano SJ
Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
18. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
19. Analysis of circulating microRNAs in adrenocortical tumors.
Szabó DR; Luconi M; Szabó PM; Tóth M; Szücs N; Horányi J; Nagy Z; Mannelli M; Patócs A; Rácz K; Igaz P
Lab Invest; 2014 Mar; 94(3):331-9. PubMed ID: 24336071
[TBL] [Abstract][Full Text] [Related]
20. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
